At the cutting edge of infertility treatment and technologies
As a leader in fertility health, EMD Serono is dedicated to providing innovative products designed with the patient in mind, that help treat infertility. While infertility can be an emotionally uncertain and frustrating journey, it can often be treated.
Nearly 20 years ago, we revolutionized the global fertility community by bringing to market the world’s first recombinant human product used in the treatment of infertility. Since that time we have brought innovations to the field of fertility drugs and are bringing our expertise into fertility technologies.
With the creation of our Fertility Technologies division, EMD Serono is using knowledge gained from working with the infertility community over many decades to address current challenges in the IVF Lab. The goal of our division is to bring a portfolio of innovative automated solutions to improve standardization and consistency to IVF labs, ultimately aiming for better outcomes for patients facing infertility.
Our first product Gidget™, a hand-held electronic witnessing and workflow visualization device, allows an embryologist to be an embryologist by helping to reduce the potential for errors and decreasing interruptions required for a manual double witness. Gidget™ provides full visibility of lab workflow and patient cycle process with seamless integration to fit within your labs existing infrastructure. To learn more download the Gidget™ brochure or watch this introductory video.
EMD Serono is committed to advancing fertility treatment beyond drugs and to further innovation in technologies by expanding our technologies portfolio in the coming years.
Important Safety Information
These products should only be prescribed by physicians specializing in fertility or reproductive health. Risks include the following events which can be serious: allergic reactions; ovarian hyperstimulation syndrome (OHSS); lung problems, blood clots, and multiple births. For complete product details about a specific fertility drug, please refer to the Full Prescribing Information for full disclosure.